Incanthera
WHAT WE DO

A revolutionary oncology company

Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies.

View what we do
SOL

Our most advanced program

The Company’s current lead product and focus is Sol, which the Company acquired in September 2018. Sol is a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

Find out more about Sol

Investors

Regulatory News

Latest News & Media

News
April 19th, 2021

Directors dealings

Read more
Presentations
December 08th, 2020

Interim results for the six months ended 30 September 2020

Read more
Press Coverage
March 23rd, 2021

Incanthera fundraise oversubscribed as it focuses on Sol deal

Read more
View All News And Media